Seller record · livevital.io

Live Vital

Recorded September 2026 · Standard v1.1

Fails 3 of 8 criteria. S3, pharmacy identification: No filling pharmacy is named. Thirty pages were read, covering terms, questions, the HIPAA notice, the telehealth consent, the peptide therapy consent and all thirteen treatment pages, and every reference stops at a licensed United States compounding pharmacy or a 503A pharmacy. 2 more criteria also fail; see the table below.

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling twelve peptides and NAD+ on ten-week protocols, prescribed by one named physician. Its semaglutide and tirzepatide pages are live and priced, and no navigation, footer or index surface on the site links to either of them.

Operating entity Live Vital, LLC

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	livevital.io/faq
S2	Prescription gating	PASS	livevital.io/treatments/tirzepatide
S3	Pharmacy identification	FAIL	livevital.io/faq
S4	Compounding disclosure	FAIL	livevital.io/treatments/tirzepatide
S5	Analytical documentation	FAIL	livevital.io/faq
S6	Business address	PASS	livevital.io/terms
S7	Price disclosure	PASS	livevital.io/treatments
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSOne physician is named, with a medical school and a residency, and the site states he reviews every intake before a protocol ships. It draws the line against research use only sellers in its own words and puts itself on the prescribed side of it.Source: livevital.io/faq.

S2PASSNo product reaches a cart. The tirzepatide assessment opens on a state-of-residence eligibility question and demands a code sent by text before any payment field, which is also where the walk stopped, so the depth of the medical screening behind that wall is not established.Source: livevital.io/treatments/tirzepatide.

S3FAILNo filling pharmacy is named. Thirty pages were read, covering terms, questions, the HIPAA notice, the telehealth consent, the peptide therapy consent and all thirteen treatment pages, and every reference stops at a licensed United States compounding pharmacy or a 503A pharmacy.Source: livevital.io/faq.

S4FAILTen of the thirteen treatment pages state that the drug is compounded and not approved by the Food and Drug Administration. The semaglutide, tirzepatide and tesamorelin pages carry neither word, and the first two name the approved brands instead.Source: livevital.io/treatments/tirzepatide.

S5FAILNo certificate, lot number or purity figure appears. Certificate terms returned zero across the thirty pages read, and 545 asset URLs hold no PDF and no image that could be one, because the whole site publishes five images.Source: livevital.io/faq.

S6PASSThe legal pages print a street address on Business Park Drive in Draper, Utah, beside a telephone number, and the site publishes no contact page at all.Source: livevital.io/terms.

S7PASSAll thirteen treatments print a price before intake, from 297 dollars for GHK-Cu to 549 dollars for tirzepatide. The monthly figure beside each total divides it by three while eleven of the thirteen protocols run ten weeks, so the two labels on one card do not describe the same period.Source: livevital.io/treatments.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: semaglutide, tirzepatide, tesamorelin, CJC-1295 with ipamorelin, BPC-157, TB-500, GHK-Cu, MOTS-c, glutathione, Glow, Klow, Wolverine, NAD+.

Unpaid link. Live Vital does not pay the site, and nothing is earned when it is used. Funding.

Visit Live Vital

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.